PneuMatters Study: Preventing early-onset pneumonia in children through maternal immunisation: a multi-centre randomised control trial (RCT)

Acute lower respiratory infections (ALRIs), including pneumonia, are one of the major causes of childhood mortality and morbidity worldwide, and early childhood infection is associated with future chronic lung disease...

Vitamin D supplementation to prevent acute respiratory infections among Indigenous children in the Northern Territory: a randomised controlled trial

Acute respiratory infections are the most common cause of hospitalisation for First Nation children in the Northern Territory. Several years ago, the Team showed that First Nation infants with lower...

Prophylactic antibiotics to prevent chest infections in children with neurological impairment (PARROT) trial

Children with neurological impairment are at high-risk of lower respiratory tract infections, leading to recurrent hospitalisations and a burden on the family and healthcare system. To prevent these lower respiratory...

Multi-centre double blind randomised controlled trial on the utility of a personalised Bronchiectasis Action Management Plan (BAMP) for children with bronchiectasis Study

Bronchiectasis is a major cause of chronic lung disease and its prevalence among Northern territory First Nations children is very high (one in every 63-68 children). Current therapies include regular...

Randomised controlled trial on duration of amoxycillin-clavulanic acid for chronic wet cough in children (DACs)

Cough is one of the most common symptoms in those seeking primary healthcare and chronic cough (>4 weeks) causes considerate morbidity and reduced quality of life. Substantial work conducted by...

Mathematical models and machine learning to identify novel predictors and pathways leading to bronchiectasis

Our current understanding of the complex pathways leading to bronchiectasis are poorly understood. Mathematical modelling and machine learning are powerful techniques that can define and identify new pathways and endotypes...

Better use of antibiotics

Antibiotics are central in the treatment of bronchiectasis. However, bronchiectasis is a heterogenous disease and therefore it is not surprising that studies previously completed by the CRE (BEST-1, BEST-2 and...

A roadmap on the clinical needs and research priorities of young people with bronchiectasis

The European Lung Foundation (ELF) undertook two surveys to help shape the future of childhood bronchiectasis, as part of the European Respiratory Society taskforce to develop a "Clinical practice guidelines...